{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:20:32Z","timestamp":1785792032091,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073859"],"award-info":[{"award-number":["82073859"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673658"],"award-info":[{"award-number":["81673658"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bcp.2024.116167","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T15:27:41Z","timestamp":1711466861000},"page":"116167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Dapagliflozin ameliorates hepatic steatosis via suppressing LXR\u03b1-mediated synthesis of lipids and bile acids"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-8426","authenticated-orcid":false,"given":"Zijie","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruotong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2024.116167_b0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.bcp.2024.116167_b0010","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.bcp.2024.116167_b0015","doi-asserted-by":"crossref","unstructured":"J.R. Schultz, et al., Role of LXRs in control of lipogenesis. Genes Dev, 2000. 14(22): p. 2831-8.https:\/\/doi.org\/10.1101\/gad.850400.","DOI":"10.1101\/gad.850400"},{"issue":"9","key":"10.1016\/j.bcp.2024.116167_b0020","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbagrm.2016.03.002","article-title":"Nuclear receptors and nonalcoholic fatty liver disease","volume":"1859","author":"Cave","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2024.116167_b0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13578-019-0339-2","article-title":"BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling","volume":"9","author":"Sheng","year":"2019","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bcp.2024.116167_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115237","article-title":"Pretreatment of hydroethanolic extract of Dillenia indica L. attenuates oleic acid induced NAFLD in HepG2 cells via modulating SIRT-1\/p-LKB-1\/AMPK, HMGCR & PPAR-alpha signaling pathways","volume":"292","author":"Poornima","year":"2022","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116167_b0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cmet.2005.03.001","article-title":"LXRs regulate the balance between fat storage and oxidation","volume":"1","author":"Kalaany","year":"2005","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.bcp.2024.116167_b0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1021\/acs.chemrestox.0c00445","article-title":"LXR\u03b1\/\u03b2 antagonism protects against lipid accumulation in the liver but increases plasma cholesterol in rhesus macaques","volume":"34","author":"Fan","year":"2021","journal-title":"Chem. Res. Toxicol."},{"issue":"18","key":"10.1016\/j.bcp.2024.116167_b0045","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1111\/bph.13933","article-title":"Morin, a novel liver X receptor alpha\/beta dual antagonist, has potent therapeutic efficacy for nonalcoholic fatty liver diseases","volume":"174","author":"Gu","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116167_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153339","article-title":"Suppression of up-regulated LXRalpha by silybin ameliorates experimental rheumatoid arthritis and abnormal lipid metabolism","volume":"80","author":"Xie","year":"2021","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.bcp.2024.116167_b0055","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional regulation of metabolic pathways via lipid-sensing Nuclear receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.bcp.2024.116167_b0060","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD short title: bile acids in meta-inflammatory disorders","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bcp.2024.116167_b0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jceh.2021.08.017","article-title":"A current understanding of bile acids in chronic liver disease","volume":"12","author":"Farooqui","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"11","key":"10.1016\/j.bcp.2024.116167_b0070","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2024.116167_b0075","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11154-019-09512-0","article-title":"Dietary lipids, gut microbiota and lipid metabolism","volume":"20","author":"Schoeler","year":"2019","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2024.116167_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.bcp.2024.116167_b0085","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s42255-021-00452-1","article-title":"Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling","volume":"3","author":"Schneider","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.bcp.2024.116167_b0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jare.2021.06.001","article-title":"Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism","volume":"34","author":"Wang","year":"2021","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bcp.2024.116167_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934136","article-title":"Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice","volume":"13","author":"Qiao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116167_b0100","first-page":"907","article-title":"Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway","author":"Luo","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116167_b0105","article-title":"Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116167_b0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bph.14859","article-title":"Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice","volume":"177","author":"Chiang","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116167_b0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study","volume":"68","author":"Tobita","year":"2021","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"8","key":"10.1016\/j.bcp.2024.116167_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.bcp.2024.116167_b0125","first-page":"943","article-title":"Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney","author":"Yuan","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116167_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174304","article-title":"Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway","volume":"907","author":"Luo","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116167_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mam.2017.06.001","article-title":"Mechanisms of bile acid mediated inflammation in the liver","volume":"56","author":"Li","year":"2017","journal-title":"Mol. Aspects Med."},{"issue":"7899","key":"10.1016\/j.bcp.2024.116167_b0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","article-title":"Low-dose metformin targets the lysosomal AMPK pathway through PEN2","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116167_b0145","doi-asserted-by":"crossref","unstructured":"H. Tilg, P.D. Cani, E.A. Mayer, Gut microbiome and liver diseases. Gut, 2016. 65(12): p. 2035-2044.https:\/\/doi.org\/10.1136\/gutjnl-2016-312729.","DOI":"10.1136\/gutjnl-2016-312729"},{"issue":"4","key":"10.1016\/j.bcp.2024.116167_b0150","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.apsb.2019.02.004","article-title":"Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters","volume":"9","author":"Sun","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bcp.2024.116167_b0155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","article-title":"Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism","volume":"7","author":"Morrison","year":"2016","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.bcp.2024.116167_b0160","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12951-021-00915-3","article-title":"Melatonin alleviates titanium nanoparticles induced osteolysis via activation of butyrate\/GPR109A signaling pathway","volume":"19","author":"Wu","year":"2021","journal-title":"J Nanobiotechnology"},{"issue":"10","key":"10.1016\/j.bcp.2024.116167_b0165","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116167_b0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.bcp.2024.116167_b0175","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"73","author":"Aso","year":"2019","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.bcp.2024.116167_b0180","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2024.116167_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109791","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.bcp.2024.116167_b0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"6","key":"10.1016\/j.bcp.2024.116167_b0195","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/me.2003-0061","article-title":"Liver X receptor signaling pathways in cardiovascular disease","volume":"17","author":"Tontonoz","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116167_b0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2015.06.042","article-title":"Liver X receptors at the intersection of lipid metabolism and atherogenesis","volume":"242","author":"Lee","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.bcp.2024.116167_b0205","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0006-291X(02)00229-2","article-title":"LXR alpha is the dominant regulator of CYP7A1 transcription","volume":"293","author":"Gupta","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2024.116167_b0210","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.dld.2018.02.012","article-title":"Actinobacteria: a relevant minority for the maintenance of gut homeostasis","volume":"50","author":"Binda","year":"2018","journal-title":"Dig. Liver Dis."},{"issue":"3","key":"10.1016\/j.bcp.2024.116167_b0215","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41396-021-01105-7","article-title":"Verrucomicrobiota are specialist consumers of sulfated methyl pentoses during diatom blooms","volume":"16","author":"Orellana","year":"2022","journal-title":"ISME J."},{"issue":"17","key":"10.1016\/j.bcp.2024.116167_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176356","article-title":"Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism","volume":"21","author":"He","year":"2020","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:23:11Z","timestamp":1728951791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":44,"alternative-id":["S0006295224001503"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116167","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin ameliorates hepatic steatosis via suppressing LXR\u03b1-mediated synthesis of lipids and bile acids","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116167"}}